HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal

Harmony Biosciences (HRMY) shares dropped 16.56% after its late-stage RECONNECT study for ZYN002 in Fragile X syndrome failed to meet its primary endpoint, primarily due to a higher-than-expected placebo response rate. This failure for the pipeline candidate, acquired via Zynerba Pharmaceuticals, contributed to HRMY's 22.2% year-to-date loss. Despite this setback, the company's lead drug Wakix generated $200.5 million in Q2, and HRMY has expanded its pipeline into rare epilepsy through the Epygenix acquisition, adding Phase III candidate EPX-100 and pre-IND EPX-200.

Analysis

Harmony Biosciences (HRMY) experienced a significant negative market reaction, with its shares declining 16.56% after announcing the failure of its late-stage RECONNECT study for ZYN002 in Fragile X syndrome. The trial for the transdermal cannabidiol gel, a pipeline candidate acquired via the 2023 Zynerba Pharmaceuticals buyout, did not meet its primary endpoint due to a high placebo response rate. This clinical setback exacerbates the stock's existing underperformance, which now stands at a 22.2% loss year-to-date against a 5.3% gain for the broader industry. However, this pipeline failure is contrasted by the robust commercial performance of its lead drug, Wakix, which generated $200.5 million in second-quarter revenue. Furthermore, the company is actively diversifying its pipeline beyond the failed asset through the recent acquisition of Epygenix Therapeutics, which adds late-stage (EPX-100) and pre-clinical (EPX-200) candidates for rare epilepsy. Critically, despite the ZYN002 news, the consensus EPS estimate for 2025 has increased by 74 cents to $6.18 in the past 90 days, indicating that analysts may be pricing in the underlying strength of the core business over this specific clinical disappointment.

Key Decisions for Investors

• Investors should assess whether the 16.56% share price drop is an overreaction, weighing the pipeline setback against the continued strong revenue from the core asset Wakix and upward revisions to 2025 EPS estimates.
• The failure of ZYN002 heightens the importance of the remaining pipeline; key catalysts to monitor include data from the pitolisant gastro-resistant study in the fourth quarter and progress updates on the newly acquired Phase III epilepsy candidate, EPX-100.
• Given the stock's significant year-to-date underperformance, the current valuation may warrant re-evaluation for those with a long-term thesis focused on the Wakix franchise and the new rare epilepsy pipeline, as the market has now fully priced out any contribution from the Fragile X program.